Kurt Haggestrom comes on to talk about the latest new from Synchron, which has developed the Stentrode as well as the new Synchron Switch. Kurt talks about his new role as Chief Commercial Officer and where the company is heading.

***This podcast is sponsored by CEITEC Nano, check out their Neurotech Device Manufacturing Capabilities here***

Top three takeaways:
 1. "The beauty of this approach is that the blood vessels are an amazing place. To be able to put implants and we've, we're leveraging really decades of science and medical devices in say, the coronary space and the heart space. We know that these types of materials heal very well within the vasculature. It's a very novel approach and really scalable because there's a lot of physicians that can do this type of procedure."

 2.   "Syncron is developing we're calling it the Synch Switch. So it is an endovascular brain-computer interface system. This system will allow patients who are suffering from paralysis to connect into the digital world, whether it's banking, communication by using a smartphone or computer.
 3. "A key part of, I think these types of novel technologies is to think about "how do people afford this when it does get to market?" And with the patients that we're focused on today, many of them use Medicare to be able to afford these technologies. It's critical that we think about our partnership and in working with CMOs to make reimbursement possible for these type of technologies.

[1:15] "Do you want to give a refresher on what Synchron does?"

[3:00]  "What are some exciting news that comes out of Synchron?"

[4:15] "So what is Chief Commercialization Officer and why is it necessary, especially for a company like Syncron which isn't commercial yet?"

[5:45] CEITEC Nano ad sponsorship

[6:15] "What's your story arc?"

[8:30] How are you navigating reimbursement?

[9:30] What is your timeline for commercialization?

[10:45] "What are some security protocols, that you're putting into place?"

[12:30] "What are some of your biggest challenges nowadays?" 

[16:15] How many patients were in your study?

[16:30] How large is the target market?

[18:15] Does this have other application potentials outside of locked in patients?

[19:15] "Is there anything that we didn't talk about that you wanted to mention?"